Next-Generation Autoimmune Therapeutics: Controlled Immune Tolerance Restorer & B/Plasma Cell-depleting OR-Gated T-Cell Engager
- ATG-207 is a first-in-class immune tolerance-inducing biologic that integrates three key design elements: 1) CD3-mediated targeting, which localizes the molecule to T cells; 2) a conformationally dynamic masking mechanism, which reduces systemic TGF-B activity; and 3) TGFBRIII-biased signaling, which further enhances selectivity toward T cells
- ATG-207 leads to coordinated immune tolerance induction – promotion of Treg differentiation and controlled attenuation of pathogenic T cell activityATG-203 is a trispecific T-cell engager, leveraging Antengene proprietary OR-gated TriGagerTM platform, which enables a broad patient coverage across CD19+ pathogenic B cell population as well the plasmablast transition zone